Leaving the parental home, cohabitation, and marriage after a hematologic malignancy in childhood-A register-based cohort study from the SALiCCS research program.

Autor: Korhonen L; Finnish Cancer Registry, Helsinki, Finland.; New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Mogensen H; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Erdmann F; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark.; Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Feychting M; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Frederiksen LE; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark., Hirvonen E; Finnish Cancer Registry, Helsinki, Finland., Krøyer A; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark., Kyrönlahti A; Finnish Cancer Registry, Helsinki, Finland.; New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Malila N; Finnish Cancer Registry, Helsinki, Finland., Pedersen C; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark., Pitkäniemi J; Finnish Cancer Registry, Helsinki, Finland.; Department of Public Health, University of Helsinki, Helsinki, Finland.; School of Health Sciences, University of Tampere, Tampere, Finland., Talbäck M; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Taskinen M; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Winther JF; Childhood Cancer Research Group, Danish Cancer Institute, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark., Madanat-Harjuoja L; Finnish Cancer Registry, Helsinki, Finland.; New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Publikováno v: Cancer medicine [Cancer Med] 2024 Aug; Vol. 13 (15), pp. e70067.

Barriers, facilitators, and other factors associated with health behaviors in childhood, adolescent, and young adult cancer survivors: A systematic review.

Autor: de Beijer IAE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Bouwman E; Department of Hematology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Mulder RL; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Steensma P; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Brown MC; Population Health Sciences Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK., Araújo-Soares V; Center for Preventive Medicine and Digital Health, Department for Prevention, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Balcerek M; Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Bardi E; St Anna Children's Hospital, Vienna, Austria.; Department of Pediatric and Adolescent Medicine, Kepler University Clinic, Linz, Austria., Falck Winther J; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.; Department of Clinical Medicine and Faculty of Health, Aarhus Universitet, Aarhus, Denmark., Frederiksen LE; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark., van Gorp M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Oberti S; DOPO clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy., van Kalsbeek RJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kepak T; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic., Kepakova K; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic., Gsell H; Childhood Cancer International Europe, Vienna, Austria., Kienesberger A; Childhood Cancer International Europe, Vienna, Austria., van Litsenburg R; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Mader L; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland., Michel G; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Muraca M; DOPO clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy., van den Oever SR; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; PanCare, Bussum, The Netherlands., Roser K; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Skinner R; Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.; Translational and Clinical Research Institute, Wolfson Childhood Cancer Research Centre, Newcastle Upon Tyne, UK., Stolman I; Department of Hematology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Uyttebroeck A; Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Leuven, Belgium., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Paediatrics, Emma Children's Hospital, Amsterdam, The Netherlands.; Faculty of Medicine, Utrecht University and Utrecht Medical Center, Utrecht, The Netherlands., Loonen J; Department of Hematology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands., van Dalen EC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Publikováno v: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (12), pp. e7361.

EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.

Autor: Helland Å; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Oncology, Oslo University Hospital, Norway., Myklebust TÅ; Department of Registration, Cancer Registry of Norway, Oslo, Norway; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway., Conte S; Medical, Biopharmaceuticals, AstraZeneca, Stockholm, Sweden., Frederiksen LE; Medical, Biopharmaceuticals, AstraZeneca, Copenhagen, Denmark., Aarøe J; Medical, Biopharmaceuticals, AstraZeneca, Oslo, Norway., Enerly E; Department of Research, Cancer Registry of Norway, Oslo, Norway. Electronic address: espen.enerly@kreftregisteret.no.

Publikováno v: Cancer treatment and research communications [Cancer Treat Res Commun] 2024; Vol. 38, pp. 100785. Date of Electronic Publication: 2023 Dec 28.

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB-IIIA Non-Small-Cell Lung Cancer Patients in Denmark.

Autor: Uldbjerg EM; Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark., Ringgaard L; AstraZeneca, 1799 Copenhagen, Denmark., Andersen KK; Omicron ApS, 2200 Copenhagen, Denmark., Frederiksen LE; AstraZeneca, 1799 Copenhagen, Denmark., Jovanovic A; Department of Experimental Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark., Meldgaard P; Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.; Institute for Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, 8200 Aarhus, Denmark.

Publikováno v: Cancers [Cancers (Basel)] 2023 Oct 25; Vol. 15 (21). Date of Electronic Publication: 2023 Oct 25.

Evaluating the feasibility, effectiveness and costs of implementing person-centred follow-up care for childhood cancer survivors in four European countries: the PanCareFollowUp Care prospective cohort study protocol.

Autor: van Kalsbeek RJ; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands R.J.vanKalsbeek@prinsesmaximacentrum.nl., Korevaar JC; Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands., Rijken M; Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands.; Department of Health and Social Care Management, University of Eastern Finland-Kuopio Campus, Kuopio, Finland., Haupt R; DOPO Clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Muraca M; DOPO Clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Kepák T; International Clinical Research Centre (FNUSA-ICRC) at St Anne's University Hospital, Masaryk University Faculty of Medicine, Brno, Czech Republic., Kepakova K; International Clinical Research Centre (FNUSA-ICRC) at St Anne's University Hospital, Masaryk University Faculty of Medicine, Brno, Czech Republic., Blondeel A; European Society for Pediatric Oncology (SIOP Europe), Brussels, Belgium., Boes S; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Frederiksen LE; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark., Essiaf S; European Society for Pediatric Oncology (SIOP Europe), Brussels, Belgium., Winther JF; Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.; Department of Clinical Medicine and Faculty of Health, Aarhus Universitet, Aarhus, Denmark., Hermens RPMG; Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboudumc, Nijmegen, The Netherlands., Kienesberger A; Childhood Cancer International Europe, Vienna, Austria., Loonen JJ; Department of Hematology, Radboudumc, Nijmegen, The Netherlands., Michel G; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Mulder RL; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands., O'Brien KB; Pintail, Limited, Dublin, Ireland., van der Pal HJH; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; PanCare, Bussum, The Netherlands., Pluijm SMF; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands., Roser K; Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland., Skinner R; Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.; Royal Victoria Infirmary, Great North Children's Hospital, Newcastle upon Tyne, UK., Renard M; Department of Paediatric Haematology and Oncology, KU Leuven, University Hospitals Leuven, Leuven, Belgium., Uyttebroeck A; Department of Paediatric Haematology and Oncology, KU Leuven, University Hospitals Leuven, Leuven, Belgium., Follin C; Department of Clinical Sciences Lund, Oncology, Lund University, Skane University Hospital, Lund, Sweden., Hjorth L; Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden., Kremer LCM; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Paediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Publikováno v: BMJ open [BMJ Open] 2022 Nov 17; Vol. 12 (11), pp. e063134. Date of Electronic Publication: 2022 Nov 17.